No Data
Jumpcan Pharmaceutical Unit's Two Drugs Added to National Insurance Catalog
hubei jumpcan pharmaceutical (600566.SH) subsidiary products include children's chiqiaoqingtang syrup and venlafaxine hydrochloride suspension powder entering the national medical insurance catalog
On December 1, Gelonghui reported that hubei jumpcan pharmaceutical (600566.SH) announced that according to the notice issued by the National Medical Insurance Administration and the Ministry of Human Resources and Social Security regarding the 'National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2024)', the products of its wholly-owned subsidiary, hubei jumpcan pharmaceutical group co., ltd., namely pediatric chichiao clearing heat syrup and fexofenadine hydrochloride dry suspension, have been included in the 'National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2024)' (hereinafter referred to as the 'National Medical Insurance Catalogue') for the first time through negotiations.
Hubei Jumpcan Pharmaceutical's (SHSE:600566) Three-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Hubei Jumpcan Pharmaceutical (SHSE:600566) Seems To Use Debt Rather Sparingly
hubei jumpcan pharmaceutical (600566.SH): In October, the company did not repurchase shares through centralized bidding trading method.
Gelonghui November 1st, hubei jumpcan pharmaceutical (600566.SH) announced that in October 2024, the company did not repurchase shares through centralized competitive trading. As of October 31, 2024, the company has repurchased a total of 180,500 shares through centralized competitive trading, accounting for 0.02% of the total share capital of the company. The highest purchase price was 29.00 yuan/share, the lowest price was 27.29 yuan/share, and the total amount paid was RMB 5,004,978 (excluding transaction costs).
Hubei Jumpcan Pharmaceutical's Q3 Profit Slides 7%; Shares Rise 4%
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
